Drugs may include antihyperglycaemic agents as glucagon-like peptide-1 receptor (GLP-1R) agonists, stimulators of the nuclear receptor peroxisome proliferator-activated receptor-γ (PPAR-γ) and inhibitors of sodium–glucose co-transporter 2 (SGLT-2), while for patients with severe obesity bariatric surgery is recommended (3). This evidence concerns the gene GLP1R and Obesity.